Study design
NSCLC, advanced/metastatic NSCLC
NSCLC
BR.36 is an international, multi-center, open-label, biomarker-directed phase 2 trial of ctDNA molecular response-adaptive immuno-chemotherapy for patients with treatment-naive NSCLC. The trial consists of two stages. In stage 1 (observational), patients with advanced/metastatic NSCLC who were eligible to receive standard-of-care single-agent pembrolizumab were enrolled in a single-arm study to evaluate, through serial liquid biopsy analyses, the optimal definition, timing and concordance of ctDNA molecular response with radiographic response (Fig. 